tradingkey.logo

Inflarx Provides Update On Phase 3 Data Analyses For Vilobelimab In Pyoderma Gangrenosum

ReutersDec 30, 2025 1:33 PM

- InflaRx NV IF0G.F:

  • INFLARX PROVIDES UPDATE ON PHASE 3 DATA ANALYSES FOR VILOBELIMAB IN PYODERMA GANGRENOSUM

  • INFLARX NV - PHASE 3 TRIAL OF VILOBELIMAB TERMINATED DUE TO FUTILITY

  • INFLARX NV: ANTICIPATES MEETING WITH FDA TO DETERMINE A POTENTIAL DEVELOPMENT PATH FORWARD IN PG

  • INFLARX: SUBSEQUENT POST-HOC ANALYSES SUGGEST POSITIVE TREND IN FAVOR OF VILOBELIMAB, WITH SIGNALS INDICATING POTENTIALLY CONSISTENT TREATMENT EFFECT

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI